Deal facts
- Buyer
- BioNTech US Inc.
- Target
- Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
- Deal value
- USD 205,000,000
- Announced
- 10 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned subsidiary of Scholar Rock Holding Corporation, which disclosed the agreement in a Form 8-K dated November 10, 2026. This is a purchase of a single asset, not an acquisition of the company or its shares.
The parties signed the asset purchase agreement on November 9, 2026. The FDA awarded the voucher to Scholar Rock on September 11, 2026, when it approved the biologics license application for ISEMBYLD (apitegromab-mstn). The 8-K reported the agreement under Item 1.01 alongside the company's third-quarter 2026 results.
BioNTech US will pay the full $205 million in cash when the sale closes. The agreement includes customary representations, warranties, covenants and indemnification provisions, subject to certain limitations.
Closing remains subject to customary conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Scholar Rock Holding Corporation said it will file the full agreement with its Annual Report on Form 10-K for the year ended December 31, 2026.
Deal timeline
1 update- Firm intention
BioNTech US Inc. firm intention to acquire Scholar Rock Inc.
Item 1.01 Entry into a Material Definitive Agreement. On November 9, 2026, Scholar Rock Holding Corporation’s (the “Company”) wholly owned subsidiary Scholar Rock Inc. (“Scholar Rock”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”) with BioNTech US Inc. (“Buyer”) pursuant to which Scholar Rock agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Abeona Therapeutics Inc. acquires APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
Abeona Therapeutics Inc. bought substantially all assets related to the research, development, manufacture and commercialization of APT-1011 from Ellodi Pharmaceuticals,…
- Buyer
- Abeona Therapeutics Inc.
- Target
- APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
- Deal value
- USD 20,000,000
- Deal type
- asset sale
CorMedix Inc. to acquire substantially all assets of Heron Therapeutics, Inc.
CorMedix Inc. (Nasdaq: CRMD) and Heron Therapeutics, Inc. (Nasdaq: HRTX) announced on 9 November 2026 that they had entered into a definitive asset purchase agreement, s…
- Buyer
- CorMedix Inc.
- Target
- Substantially all assets of Heron Therapeutics, Inc.
- Deal value
- USD 222,600,000
- Deal type
- asset sale
Rockwell Medical, Inc. to acquire Vantive's in-center hemodialysis business
Rockwell Medical, Inc. signed an Equity and Asset Purchase Agreement on November 2, 2026 with Vantive Limited, a Jersey company, to acquire Vantive's in-center hemodialy…
- Buyer
- Rockwell Medical, Inc.
- Target
- Vantive in-center hemodialysis business
- Deal value
- USD 125,000,000
- Deal type
- asset sale
Biossil Labs Inc. to acquire Theriva Biologics' ribaxamase and SYN-006 assets
Theriva Biologics, Inc. (NYSE American: TOVX) sold its ribaxamase program to Biossil Labs Inc., a corporation organized under the laws of Canada, under an Asset Purchase…
- Buyer
- Biossil Labs Inc.
- Target
- Theriva Biologics ribaxamase and SYN-006 assets
- Deal value
- USD 350,000
- Deal type
- asset sale
VoxelDox Therapeutics, Inc. to acquire Imunon, Inc.
VoxelDox Therapeutics, Inc. has agreed to acquire assets from Imunon, Inc. in a transaction announced on 21 October 2026. Both companies are based in the United States a…
- Buyer
- VoxelDox Therapeutics, Inc.
- Target
- Imunon, Inc.
- Deal value
- Not disclosed
- Deal type
- asset sale
Buyer history
BioNTech US Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive